RYR1 and neoplasm: Apart from the predictors mentioned above, CD8+ T-cell tumor-infiltrating, genetic mutations (RYR1, MGAM and STK11), copy number alteration and HLA class I diversity are also being explored for treating NSCLC and other solid tumors.84,97–99 Taken together, there cannot be a single perfect predictor to screen potential target populations for immunotherapy in NSCLC; predictive models are needed that take into account different parameters affecting tumor-host interactions.